- Home
- IBIO vs TXMD Comparison
IBIO vs TXMD Comparison
Compare IBIO & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- TXMD
- Stock Information
- Founded
- IBIO 2008
- TXMD 2008
- Country
- IBIO United States
- TXMD United States
- Employees
- IBIO N/A
- TXMD N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- IBIO Health Care
- TXMD Health Care
- Exchange
- IBIO Nasdaq
- TXMD Nasdaq
- Market Cap
- IBIO 11.9M
- TXMD 12.7M
- IPO Year
- IBIO N/A
- TXMD N/A
- Fundamental
- Price
- IBIO $0.79
- TXMD $1.10
- Analyst Decision
- IBIO Strong Buy
- TXMD
- Analyst Count
- IBIO 2
- TXMD 0
- Target Price
- IBIO $5.50
- TXMD N/A
- AVG Volume (30 Days)
- IBIO 723.2K
- TXMD 18.8K
- Earning Date
- IBIO 09-19-2025
- TXMD 08-12-2025
- Dividend Yield
- IBIO N/A
- TXMD N/A
- EPS Growth
- IBIO N/A
- TXMD N/A
- EPS
- IBIO N/A
- TXMD N/A
- Revenue
- IBIO $375,000.00
- TXMD $2,559,000.00
- Revenue This Year
- IBIO $81.33
- TXMD $427.09
- Revenue Next Year
- IBIO N/A
- TXMD N/A
- P/E Ratio
- IBIO N/A
- TXMD N/A
- Revenue Growth
- IBIO 650.00
- TXMD 156.93
- 52 Week Low
- IBIO $0.56
- TXMD $0.70
- 52 Week High
- IBIO $6.89
- TXMD $2.44
- Technical
- Relative Strength Index (RSI)
- IBIO 60.85
- TXMD 45.09
- Support Level
- IBIO $0.67
- TXMD $1.06
- Resistance Level
- IBIO $0.81
- TXMD $1.12
- Average True Range (ATR)
- IBIO 0.07
- TXMD 0.05
- MACD
- IBIO 0.02
- TXMD -0.00
- Stochastic Oscillator
- IBIO 89.29
- TXMD 35.92
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.